ETON Stock Analysis: Buy, Sell, or Hold?
ETON - Eton Pharmaceutcials, Inc. Common Stock
$37.34
0.73 (1.99%)
▲
5d:
-1.79%
30d:
+20.65%
90d:
+41.65%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When ETON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ETON shows positive signals but monitor for confirmation. Market pricing in 5.8% growth. Moderate conviction.
💡 BUY OPPORTUNITY: ETON shows positive signals but monitor for confirmation. Market pricing in 5.8% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$61.51
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$38.19
2.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ETON is currently trading at $37.34, which is considered extended relative to its 30-day fair value range of $31.17 to $36.82. From a valuation perspective, the stock is trading at a premium (Forward PE: 19.9) compared to its historical average (16.8). At these levels, the market is pricing in 5.8% annual earnings growth.
Technical Outlook: Technically, ETON is in a strong uptrend. Immediate support is located at $34.85, while resistance sits at $38.62.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $45.67 (+22.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ETON is in a strong uptrend. Immediate support is located at $34.85, while resistance sits at $38.62.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $45.67 (+22.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$31.17 -
$36.82
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.3% below Wall St target ($45.67)
- BULLISH: Expecting earnings turnaround to 5.8% growth with 40.4% revenue growth
Trading Range Analysis
30-Day Trading Range
$31.17 -
$36.82
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.41
(9.1%)
Support & Resistance Levels
Support Level
$34.85
Resistance Level
$38.62
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.86
Wall Street Target
$45.67
(+22.3%)
Revenue Growth (YoY)
40.4%
Earnings Growth (YoY)
-12.6%
Profit Margin
-1.7%
Valuation Premium vs History
+5.8% premium
PE vs Historical
19.9 vs 16.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.8%
(market-implied from PE analysis)
1-Year Target
$39.51
(+6%)
2-Year Target
$41.80
(+12%)
3-Year Target
$44.22
(+18%)
3-Yr Target (if PE normalizes)
(PE: 20→17)
PE COMPRESSION
$37.40
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 86.1%)
$138.19
(+270%)
Base:
(SPY PE: 19.9, Growth: 86.1%)
$126.02
(+238%)
Bear:
(PE: 16.8, Growth: 86.1%)
$106.60
(+186%)
Share & Embed Analysis
Last updated: July 13, 2026 9:29 PM ET
Data refreshes hourly during market hours. Next update: 10:29 PM
Data refreshes hourly during market hours. Next update: 10:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ETON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
